Regarding its impact on prognosis, CRC patients with BRAF exon 15 p.V600E mutations show lower OS, DFS, and cancer-specific survival (CSS) rates than wild-type patients, despite the stage of the disease (II or III) or the adoption of chemotherapeutic regimens after surgery [104]. This evidence concerns the gene BRAF and colorectal carcinoma.